Dr. Hamlin on Toxicities Associated With Ibrutinib and Buparlisib in MCL, FL, and DLBCL

Paul A. Hamlin, MD
Published: Wednesday, Aug 09, 2017



Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses the toxicities reported in a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Both buparlisib and ibrutinib (Imbruvica) have known toxicities, Hamlin explains. When combined, fatigue, gastrointestinal complaints, and rash were the most common toxicities reported. These were reduced with dose reductions. Buparlisib, he adds, is also associated with mood disturbances as well, which were also reported on the study.

Both of these small molecule inhibitors have mechanisms of resistance, creating the synergy between the two, he says.


Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses the toxicities reported in a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Both buparlisib and ibrutinib (Imbruvica) have known toxicities, Hamlin explains. When combined, fatigue, gastrointestinal complaints, and rash were the most common toxicities reported. These were reduced with dose reductions. Buparlisib, he adds, is also associated with mood disturbances as well, which were also reported on the study.

Both of these small molecule inhibitors have mechanisms of resistance, creating the synergy between the two, he says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x